Regulatory News:
Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2020:
- 23,398 shares
- € 174,109.53
- Number of executions on buy side on semester: 791
- Number of executions on sell side on semester: 778
- Traded volume on buy side on semester: 73,482 shares for € 670,186.50
- Traded volume on sell side on semester: 71,922 shares for € 780,030.28
As a reminder:
• the following resources appeared on the last half year statement on December 31st 2019 on the liquidity account:
- 21,838 shares
- € 64,556.58
- Number of executions on buy side on semester : 374
- Number of executions on sell side on semester : 289
- Traded volume on buy side on semester : 32,784 shares for € 230,115.00
- Traded volume on sell side on semester : 27,816 shares for € 201,203.25
• the following resources appeared on the liquidity account when the activity started :
- 0 shares
- € 200,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
| Buy Side |
| Sell Side | ||||
Number of
|
Number of
|
Traded volume
|
Number of
|
Number of
|
Traded volume
| ||
Total | 791 | 73,482 | 670,186.50 | 778 | 71,922 | 780,030.28 | |
02/01/2020 | 2 | 251 | 1,731.90 | 8 | 1,199 | 8,357.03 | |
03/01/2020 | 7 | 1,013 | 6,868.14 | 1 | 1 | 6.90 | |
06/01/2020 | 4 | 457 | 3,093.89 | 6 | 750 | 5,175.00 | |
07/01/2020 | 2 | 44 | 296.56 | 1 | 1 | 6.78 | |
08/01/2020 | 5 | 767 | 5,062.20 | 1 | 1 | 6.60 | |
09/01/2020 | 1 | 1 | 6.68 | 5 | 347 | 2,324.90 | |
10/01/2020 | 2 | 600 | 3,960.00 | 5 | 1,023 | 6,864.33 | |
13/01/2020 | 1 | 13 | 85.80 | 4 | 500 | 3,350.00 | |
14/01/2020 | - | - | - | 1 | 15 | 101.40 | |
15/01/2020 | - | - | - | 1 | 116 | 784.16 | |
16/01/2020 | 2 | 21 | 139.65 | 1 | 1 | 6.76 | |
17/01/2020 | 2 | 21 | 139.44 | 1 | 1 | 6.66 | |
20/01/2020 | 1 | 63 | 418.32 | - | - | - | |
21/01/2020 | 1 | 1 | 6.66 | 1 | 1 | 6.66 | |
22/01/2020 | 5 | 485 | 3,210.70 | 1 | 1 | 6.66 | |
23/01/2020 | 1 | 1 | 6.60 | 1 | 1 | 6.60 | |
24/01/2020 | 6 | 725 | 4,719.75 | 1 | 1 | 6.60 | |
27/01/2020 | 1 | 1 | 6.52 | 1 | 1 | 6.52 | |
28/01/2020 | 5 | 387 | 2,484.54 | 1 | 1 | 6.44 | |
29/01/2020 | 1 | 1 | 6.44 | 3 | 251 | 1,646.56 | |
30/01/2020 | 1 | 50 | 325.00 | 2 | 320 | 2,115.20 | |
31/01/2020 | 1 | 1 | 6.54 | 1 | 1 | 6.54 | |
03/02/2020 | 3 | 180 | 1,170.00 | 1 | 1 | 6.64 | |
04/02/2020 | 1 | 1 | 6.64 | 3 | 181 | 1,205.46 | |
05/02/2020 | 3 | 116 | 755.16 | 1 | 1 | 6.66 | |
07/02/2020 | 1 | 1 | 6.62 | 1 | 1 | 6.62 | |
10/02/2020 | 2 | 160 | 1,040.00 | 1 | 1 | 6.66 | |
11/02/2020 | 1 | 1 | 6.46 | 1 | 1 | 6.46 | |
12/02/2020 | - | - | - | 1 | 250 | 1,650.00 | |
13/02/2020 | 2 | 251 | 1,631.50 | 2 | 251 | 1,656.60 | |
14/02/2020 | 1 | 1 | 6.62 | 1 | 1 | 6.62 | |
18/02/2020 | 1 | 1 | 6.50 | - | - | - | |
19/02/2020 | 1 | 1 | 6.58 | 1 | 1 | 6.58 | |
20/02/2020 | 1 | 1 | 6.60 | 1 | 1 | 6.60 | |
21/02/2020 | 1 | 1 | 6.58 | 1 | 1 | 6.58 | |
25/02/2020 | 2 | 51 | 336.60 | 5 | 266 | 1,771.56 | |
26/02/2020 | 6 | 451 | 2,976.60 | 5 | 735 | 4,917.15 | |
27/02/2020 | 1 | 1 | 6.72 | 2 | 196 | 1,324.96 | |
28/02/2020 | 5 | 501 | 3,316.62 | 1 | 1 | 6.70 | |
02/03/2020 | 1 | 1 | 6.62 | 3 | 223 | 1,494.10 | |
03/03/2020 | - | - | - | 2 | 78 | 525.72 | |
04/03/2020 | 1 | 1 | 6.68 | 1 | 1 | 6.68 | |
06/03/2020 | 11 | 934 | 6,127.04 | 1 | 5 | 33.00 | |
09/03/2020 | 1 | 1 | 6.58 | 3 | 246 | 1,623.60 | |
10/03/2020 | 6 | 652 | 4,224.96 | 1 | 1 | 6.58 | |
11/03/2020 | 3 | 601 | 3,798.32 | 1 | 1 | 6.50 | |
12/03/2020 | 3 | 300 | 1,872.00 | - | - | - | |
13/03/2020 | 16 | 3,263 | 19,382.22 | 1 | 75 | 472.50 | |
16/03/2020 | 24 | 2,601 | 13,161.06 | 1 | 1 | 5.40 | |
17/03/2020 | 4 | 300 | 1,341.00 | 7 | 727 | 3,722.24 | |
19/03/2020 | 1 | 1 | 5.04 | 5 | 322 | 1,719.48 | |
20/03/2020 | 1 | 100 | 520.00 |
| 6 | 402 | 2,182.86 |
23/03/2020 | 2 | 51 | 270.30 |
| 1 | 1 | 5.46 |
24/03/2020 | 1 | 1 | 5.32 | 3 | 52 | 286.00 | |
25/03/2020 | 1 | 150 | 795.00 | 5 | 488 | 2,674.24 | |
26/03/2020 | - | - | - | 10 | 911 | 5,174.48 | |
27/03/2020 | - | - | - | 3 | 272 | 1,577.60 | |
30/03/2020 | - | - | - | 8 | 728 | 4,302.48 | |
01/04/2020 | 1 | 1 | 5.94 | 1 | 1 | 5.94 | |
02/04/2020 | 1 | 1 | 5.94 | 1 | 1 | 5.94 | |
03/04/2020 | - | - | - | 6 | 338 | 2,034.76 | |
06/04/2020 | - | - | - | 4 | 188 | 1,141.16 | |
07/04/2020 | - | - | - | 68 | 9,600 | 97,056.00 | |
08/04/2020 | - | - | - | 74 | 6,400 | 128,000.00 | |
14/04/2020 | 17 | 700 | 9,660.00 | 2 | 155 | 2,331.20 | |
15/04/2020 | 22 | 1,700 | 21,930.00 | 8 | 445 | 6,283.40 | |
16/04/2020 | 34 | 2,300 | 27,025.00 | 56 | 3,304 | 44,108.40 | |
17/04/2020 | 19 | 1,300 | 16,458.00 | 8 | 453 | 6,065.67 | |
20/04/2020 | 11 | 700 | 8,540.00 | 4 | 156 | 2,087.28 | |
21/04/2020 | 28 | 1,600 | 17,648.00 | 58 | 4,587 | 60,273.18 | |
22/04/2020 | 16 | 1,500 | 19,320.00 | 12 | 800 | 10,888.00 | |
23/04/2020 | 73 | 5,400 | 68,526.00 | 35 | 2,300 | 33,465.00 | |
24/04/2020 | 7 | 600 | 6,492.00 | 13 | 400 | 4,660.00 | |
27/04/2020 | 4 | 400 | 4,300.00 | 2 | 100 | 1,180.00 | |
28/04/2020 | 34 | 2,700 | 30,915.00 | 35 | 2,900 | 35,496.00 | |
30/04/2020 | 5 | 500 | 5,300.00 | 1 | 100 | 1,145.00 | |
04/05/2020 | 35 | 2,700 | 25,785.00 | 19 | 1,100 | 10,780.00 | |
05/05/2020 | 8 | 400 | 3,840.00 | 5 | 287 | 2,832.69 | |
06/05/2020 | 28 | 2,202 | 22,658.58 | 56 | 5,300 | 61,692.00 | |
07/05/2020 | 34 | 3,398 | 33,606.22 | 6 | 1,200 | 12,216.00 | |
08/05/2020 | 6 | 500 | 4,990.00 | 9 | 900 | 9,297.00 | |
11/05/2020 | 19 | 2,000 | 19,040.00 | - | - | - | |
12/05/2020 | 17 | 2,400 | 20,712.00 | - | - | - | |
13/05/2020 | 21 | 2,300 | 19,021.00 | 43 | 6,300 | 59,472.00 | |
14/05/2020 | 6 | 950 | 8,284.00 | 2 | 200 | 1,860.00 | |
15/05/2020 | 13 | 1,900 | 16,511.00 | 1 | 200 | 1,904.00 | |
18/05/2020 | 9 | 1,000 | 8,640.00 | - | - | - | |
19/05/2020 | 10 | 800 | 6,792.00 | - | - | - | |
20/05/2020 | 7 | 800 | 6,520.00 | 13 | 1,900 | 17,879.00 | |
21/05/2020 | 5 | 800 | 7,280.00 | - | - | - | |
22/05/2020 | 11 | 601 | 5,439.05 | 1 | 1 | 9.20 | |
25/05/2020 | 2 | 400 | 3,500.00 | - | - | - | |
26/05/2020 | - | - | - | 1 | 200 | 1,820.00 | |
27/05/2020 | 6 | 1,000 | 8,680.00 | - | - | - | |
28/05/2020 | 7 | 800 | 7,160.00 | 13 | 2,000 | 18,400.00 | |
29/05/2020 | 5 | 600 | 5,220.00 | - | - | - | |
01/06/2020 | 4 | 200 | 1,700.00 | - | - | - | |
02/06/2020 | 4 | 400 | 3,420.00 | 4 | 400 | 3,540.00 | |
03/06/2020 | 10 | 600 | 5,094.00 | 3 | 200 | 1,720.00 | |
04/06/2020 | 13 | 1,200 | 9,780.00 | 5 | 800 | 6,632.00 | |
05/06/2020 | 21 | 3,200 | 25,152.00 | 11 | 1,600 | 13,040.00 | |
08/06/2020 | 8 | 650 | 5,505.50 | 15 | 1,400 | 12,082.00 | |
09/06/2020 | 3 | 400 | 3,380.00 | 4 | 450 | 3,888.00 | |
10/06/2020 | 1 | 200 | 1,740.00 | 7 | 600 | 5,286.00 | |
11/06/2020 | 7 | 600 | 5,100.00 | - | - | - | |
12/06/2020 | 1 | 200 | 1,680.00 | 1 | 200 | 1,720.00 | |
15/06/2020 | 8 | 1,300 | 10,803.00 | - | - | - | |
16/06/2020 | 1 | 200 | 1,620.00 | 2 | 200 | 1,660.00 | |
17/06/2020 | 1 | 200 | 1,680.00 |
| 6 | 900 | 7,677.00 |
18/06/2020 | 2 | 400 | 3,300.00 | - | - | - | |
19/06/2020 | 1 | 200 | 1,660.00 | 5 | 400 | 3,380.00 | |
23/06/2020 | 4 | 400 | 3,260.00 | - | - | - | |
24/06/2020 | 1 | 200 | 1,600.00 | - | - | - | |
25/06/2020 | 4 | 400 | 3,140.00 | 2 | 321 | 2,580.84 | |
26/06/2020 | 1 | 200 | 1,560.00 | - | - | - | |
29/06/2020 | 10 | 1,200 | 9,144.00 | 5 | 810 | 6,318.00 | |
30/06/2020 | 6 | 600 | 4,680.00 | 14 | 869 | 6,908.55 |
About MedinCell
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005810/en/